Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Core Insights - Biomea Fusion, Inc. presented new preclinical and clinical data for icovamenib, an investigational oral menin inhibitor, at the 85th Scientific Sessions of the American Diabetes Association [1][2] - The data highlights icovamenib's potential to enhance glycemic control and promote weight loss while preserving lean mass, particularly when used in combination with GLP-1 receptor agonists [3][4] Presentation Summaries - The combination of icovamenib and low-dose semaglutide showed superior metabolic benefits in a Type 2 Diabetes animal model, suggesting that icovamenib can enhance the effects of GLP-1 therapies [4] - Icovamenib demonstrated the ability to rescue human myotube atrophy and preserve lean mass in a Type 2 Diabetes rat model, indicating its potential for muscle health [5][6] - In the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide at Week 26, showcasing its efficacy in insulin-deficient patients [6][14] Key Findings - Icovamenib led to a 60% reduction in fasting blood glucose and a 50% lower glucose OGTT AUC, with significant improvements in insulin sensitivity and appetite suppression [7] - The treatment resulted in a greater than 1% decline in HbA1c by Day 28 and over 2% by Day 39, indicating its effectiveness in glycemic control [7] - The combination therapy with GLP-1-based treatments allows for lower doses to achieve desired glycemic and weight loss targets, enhancing tolerability [4][8] Mechanism of Action - Icovamenib is designed to inhibit menin, which is believed to support the regeneration of insulin-producing beta cells, potentially halting or reversing the progression of Type 2 Diabetes [11][16] - The drug's mechanism aims to promote the proliferation and preservation of healthy beta cells, making it a candidate for disease-modifying therapy in diabetes [16] Company Overview - Biomea Fusion is focused on developing oral small molecules, including icovamenib and BMF-650, aimed at improving the lives of patients with diabetes, obesity, and metabolic diseases [17]